|
|
||||||||
1 Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles 90059; 2 Laboratory for Exercise Sciences, El Camino College, and 3 Harbor-University of California Los Angeles Medical Center, Torrance, California 90502; and 4 Biomedical Mass Spectrometric Research Resource, Department of Internal Medicine, Washington University, School of Medicine, St. Louis, Missouri 63110
Testosterone increases muscle mass and strength and regulates other physiological processes, but we do not know whether testosterone effects are dose dependent and whether dose requirements for maintaining various androgen-dependent processes are similar. To determine the effects of graded doses of testosterone on body composition, muscle size, strength, power, sexual and cognitive functions, prostate-specific antigen (PSA), plasma lipids, hemoglobin, and insulin-like growth factor I (IGF-I) levels, 61 eugonadal men, 18-35 yr, were randomized to one of five groups to receive monthly injections of a long-acting gonadotropin-releasing hormone (GnRH) agonist, to suppress endogenous testosterone secretion, and weekly injections of 25, 50, 125, 300, or 600 mg of testosterone enanthate for 20 wk. Energy and protein intakes were standardized. The administration of the GnRH agonist plus graded doses of testosterone resulted in mean nadir testosterone concentrations of 253, 306, 542, 1,345, and 2,370 ng/dl at the 25-, 50-, 125-, 300-, and 600-mg doses, respectively. Fat-free mass increased dose dependently in men receiving 125, 300, or 600 mg of testosterone weekly (change +3.4, 5.2, and 7.9 kg, respectively). The changes in fat-free mass were highly dependent on testosterone dose (P = 0.0001) and correlated with log testosterone concentrations (r = 0.73, P = 0.0001). Changes in leg press strength, leg power, thigh and quadriceps muscle volumes, hemoglobin, and IGF-I were positively correlated with testosterone concentrations, whereas changes in fat mass and plasma high-density lipoprotein (HDL) cholesterol were negatively correlated. Sexual function, visual-spatial cognition and mood, and PSA levels did not change significantly at any dose. We conclude that changes in circulating testosterone concentrations, induced by GnRH agonist and testosterone administration, are associated with testosterone dose- and concentration-dependent changes in fat-free mass, muscle size, strength and power, fat mass, hemoglobin, HDL cholesterol, and IGF-I levels, in conformity with a single linear dose-response relationship. However, different androgen-dependent processes have different testosterone dose-response relationships.
sexual function; testosterone effects on muscle; cognitive function; plasma lipids; prostate-specific antigen; testosterone effects on insulin-like growth factor I; testosterone and hemoglobin
This article has been cited by other articles:
![]() |
M. Brown Skeletal muscle and bone: effect of sex steroids and aging Advan Physiol Educ, June 1, 2008; 32(2): 120 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Knapp, T. W. Storer, K. L. Herbst, A. B. Singh, C. Dzekov, J. Dzekov, M. LaValley, A. Zhang, J. Ulloor, and S. Bhasin Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1135 - E1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Dayton and M. E. White Cellular and molecular regulation of muscle growth and development in meat animals J Anim Sci, April 1, 2008; 86(14_suppl): E217 - E225. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Saad, L. J. Gooren, A. Haider, and A. Yassin A Dose-Response Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone Undecanoate J Androl, January 1, 2008; 29(1): 102 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Muniyappa, J. D. Sorkin, J. D. Veldhuis, S. M. Harman, T. Munzer, S. Bhasin, and M. R. Blackman Long-term testosterone supplementation augments overnight growth hormone secretion in healthy older men Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E769 - E775. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Ries, G. S. Bauldoff, B. W. Carlin, R. Casaburi, C. F. Emery, D. A. Mahler, B. Make, C. L. Rochester, R. ZuWallack, and C. Herrerias Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines Chest, May 1, 2007; 131(5_suppl): 4S - 42S. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Katznelson, M. W Robinson, C. L Coyle, H. Lee, and C. E Farrell Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men Eur. J. Endocrinol., December 1, 2006; 155(6): 867 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kvorning, M. Andersen, K. Brixen, and K. Madsen Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1325 - E1332. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Marks, N. A. Mazer, E. Mostaghel, D. L. Hess, F. J. Dorey, J. I. Epstein, R. W. Veltri, D. V. Makarov, A. W. Partin, D. G. Bostwick, et al. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial. JAMA, November 15, 2006; 296(19): 2351 - 2361. [Abstract] [Full Text] [PDF] |
||||
![]() |
A M Solomon and P M G Bouloux Modifying muscle mass - the endocrine perspective. J. Endocrinol., November 1, 2006; 191(2): 349 - 360. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Orwoll, L. C. Lambert, L. M. Marshall, J. Blank, E. Barrett-Connor, J. Cauley, K. Ensrud, S. R. Cummings, and for the Osteoporotic Fractures in Men Study Group Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med, October 23, 2006; 166(19): 2124 - 2131. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Axell, H. E. MacLean, D. R. Plant, L. J. Harcourt, J. A. Davis, M. Jimenez, D. J. Handelsman, G. S. Lynch, and J. D. Zajac Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E506 - E516. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Matthiesson and R. I. McLachlan Male hormonal contraception: concept proven, product in sight? Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Casaburi, L. Cosentino, J. Porszasz, M. I. Lewis, M. Fournier, and T. W. Storer Testosterone Supplementation during Respiratory Rehabilitation Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 399 - 400. [Full Text] [PDF] |
||||
![]() |
T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38. [Full Text] [PDF] |
||||
![]() |
S. T. Page, K. L. Herbst, J. K. Amory, A. D. Coviello, B. D. Anawalt, A. M. Matsumoto, and W. J. Bremner Testosterone Administration Suppresses Adiponectin Levels in Men J Androl, January 1, 2005; 26(1): 85 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Seftel, R. J. Mack, A. R. Secrest, and T. M. Smith Restorative Increases in Serum Testosterone Levels Are Significantly Correlated to Improvements in Sexual Functioning J Androl, November 1, 2004; 25(6): 963 - 972. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Casaburi, S. Bhasin, L. Cosentino, J. Porszasz, A. Somfay, M. I. Lewis, M. Fournier, and T. W. Storer Effects of Testosterone and Resistance Training in Men with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 870 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Guralnik, R. S. Eisenstaedt, L. Ferrucci, H. G. Klein, and R. C. Woodman Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia Blood, October 15, 2004; 104(8): 2263 - 2268. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Nieschlag, H.M. Behre, P. Bouchard, J.J. Corrales, T.H. Jones, G.K. Stalla, S.M. Webb, and F.C.W. Wu Testosterone replacement therapy: current trends and future directions Hum. Reprod. Update, September 1, 2004; 10(5): 409 - 419. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Hartgens, G Rietjens, H A Keizer, H Kuipers, and B H R Wolffenbuttel Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) Br. J. Sports Med., June 1, 2004; 38(3): 253 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Asthana, S. Bhasin, R. N. Butler, H. Fillit, J. Finkelstein, S. M. Harman, L. Holstein, S. G. Korenman, A. M. Matsumoto, J. E. Morley, et al. Masculine Vitality: Pros and Cons of Testosterone in Treating the Andropause J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2004; 59(5): M461 - M465. [Full Text] [PDF] |
||||
![]() |
E. C. Tsai, A. M. Matsumoto, W. Y. Fujimoto, and E. J. Boyko Association of Bioavailable, Free, and Total Testosterone With Insulin Resistance: Influence of sex hormone-binding globulin and body fat Diabetes Care, April 1, 2004; 27(4): 861 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Schroeder, L. Zheng, K. E. Yarasheski, D. Qian, Y. Stewart, C. Flores, C. Martinez, M. Terk, and F. R. Sattler Treatment with oxandrolone and the durability of effects in older men J Appl Physiol, March 1, 2004; 96(3): 1055 - 1062. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Evans Current Concepts in Anabolic-Androgenic Steroids Am. J. Sports Med., March 1, 2004; 32(2): 534 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bhasin, W. E. Taylor, R. Singh, J. Artaza, I. Sinha-Hikim, R. Jasuja, H. Choi, and N. F. Gonzalez-Cadavid The Mechanisms of Androgen Effects on Body Composition: Mesenchymal Pluripotent Cell as the Target of Androgen Action J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2003; 58(12): M1103 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bhasin Testosterone Supplementation for Aging-Associated Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2003; 58(11): M1002 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Wittert, I. M. Chapman, M. T. Haren, S. Mackintosh, P. Coates, and J. E. Morley Oral Testosterone Supplementation Increases Muscle and Decreases Fat Mass in Healthy Elderly Males With Low-Normal Gonadal Status J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2003; 58(7): M618 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Schroeder, M. Terk, and F. R. Sattler Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E16 - E24. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sinha-Hikim, S. M. Roth, M. I. Lee, and S. Bhasin Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E197 - E205. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Herbst, J. K. Amory, J. D. Brunzell, H. A. Chansky, and W. J. Bremner Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1112 - E1118. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF] |
||||
![]() |
L. J. Woodhouse, S. Reisz-Porszasz, M. Javanbakht, T. W. Storer, M. Lee, H. Zerounian, and S. Bhasin Development of models to predict anabolic response to testosterone administration in healthy young men Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1009 - E1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Schroeder, A. Singh, S. Bhasin, T. W. Storer, C. Azen, T. Davidson, C. Martinez, I. Sinha-Hikim, S. V. Jaque, M. Terk, et al. Effects of an oral androgen on muscle and metabolism in older, community-dwelling men Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E120 - E128. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. R. Sattler, E. T. Schroeder, M. P. Dube, S. V. Jaque, C. Martinez, P. J. Blanche, S. Azen, and R. M. Krauss Metabolic effects of nandrolone decanoate and resistance training in men with HIV Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1214 - E1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sinha-Hikim, J. Artaza, L. Woodhouse, N. Gonzalez-Cadavid, A. B. Singh, M. I. Lee, T. W. Storer, R. Casaburi, R. Shen, and S. Bhasin Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy Am J Physiol Endocrinol Metab, July 1, 2002; 283(1): E154 - E164. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |